Slide 1: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 2: Two Companies
Two Companies •Simulations Plus, Inc. (AMEX:SLP)-Founded 1996 out of Words+, Inc. -global business-IPO June 1997 -no further financing to date-Software for pharmaceutical research and development-Consulting studies for pharmaceutical and drug delivery companies-FutureLab simulations for middle-and h
Slide 3: Simulations Plus, Inc.
Simulations Plus, Inc. Simulation and modeling software for pharmaceutical research-ADMET Predictor™/ADMET Modeler™-ClassPharmer™-DDDPlus™-GastroPlus™Consulting services to the pharmaceutical industry
Slide 4: ADMET Predictor
ADMET Predictor TM Predicts numerous properties of molecules from just their structures, including physicochemical properties and several toxicities•Ranked #1 in accuracy in two independent studies for predicting solubility and logP•Again ranked #1 for logP predictions in German study in January 200
Slide 5: ADMET Modeler
ADMET Modeler TM •Integrated with ADMET Predictor -provides complete modeling/prediction capability -used to •Speedand model qualityunsurpassed -contract studies have shown ability to find useful models from user data (including activity) when others have failed•Strategy going forward:-Keep up with
Slide 6: ClassPharmer
ClassPharmer TM •Merge of two products acquired in 2005 -New product is dramatically faster, more flexible, and can process much larger chemical libraries•Can help chemists identify what it is about molecular structuresthat cause good or bad properties -finds “maximum common substructures” in classe
Slide 7: DDDPlus
DDDPlus TM •Sales continue to come in -industry is learning how to use this unique tool•Strategy going forward:-Continue aggressive marketing and sales activities•Educate formulation scientists on how to use simulation in theirwork•Emphasize compatibility with GastroPlus for formulation studies-Hold
Slide 8: GastroPlus
GastroPlus TM •The industry’s Gold Standard -most advanced and widely used simulation of oral absorption/pharmacokinetics/pharmacodynamics•Strategy going forward:-Ongoing effort to push the state-of-the-art in PBPK modeling is producing excellent results-New features added, including the ability to
Slide 9: Consulting Contracts
Consulting Contracts •Growing part of business -Simulation studies •Troubleshooting problem compounds •Virtual bioequivalence trials •Design of new oral dosage formulations -Structure-property modeling •Generates leads for software licenses •Identifies unmet needs for software improvements •Increase
Slide 10: Core Capabilities and Strengths
Core Capabilities and Strengths -Growing team of exceptional scientists and engineers•Chemistry, biochemistry, molecular biology•Chemical engineering, biomedical engineering•Computer science•Augmentative communication (Words+ subsidiary)-Recognized world-class expertise in oral drug delivery, pharma
Slide 11: Some of Our International Pharma Customers
Some of Our International Pharma Customers
Slide 12: Selected Income Statement Data
Selected Income Statement Data (in millions except per share data) 3Q Ended 5/31/07 3Q Ended 5/31/06 2Q Ended 2/28/07 2Q Ended 2/28/06 1Q Ended 11/30/06 1Q Ended 11/30/05 4Q Ended 8/31/06 4Q Ended 8/31/05 Revenues $2.631 $1.788 $2.534 $1.482 $1.456 $0.819 $1.766 $1.230 Cost of Sales 0.551 0.4330.557
Slide 13: Guidance
Guidance •We are increasing our revenues estimate for the fiscal year to an increase of at least $2.9 million over last fiscal year •Although we have always managed to exceed our estimates in the past, there is no guarantee that we will meet this estimate!
Slide 14: Balance Sheet
Balance Sheet (in millions) As of May 31, 2007ASSETSLIABILITIESCash & cash equivalents $ 3.038Accounts payable$ 0.089Accounts receivable 2.864Accrued expenses0.711Other current assets0.590Current portion deferred revenue0.073TOTAL CURRENT ASSETS6.492Other current liabilities-TOTAL CURRENT LIAB.0.873
Slide 15: Revenue History
Revenue History -1,000,0002,000,0003,000,0004,000,0005,000,0006,000,0007,000,000$98990001020304050607(9M)Fiscal Year Revenue Words+Simulations Plus Consolidated
Slide 16: Strategic Considerations
Strategic Considerations •Aggressive marketing and sales activities have paid off, and will continue •Cash position continues to improve -we want to use it to acquire, to continue to hire selected staff, and for possible outsourcing of specific activities to augment internal efforts • Ongoing hunt,
Slide 17: Management & Directors
Management & Directors •Walter S. Woltosz , M.S., M.A.S., Chairman & CEO •Momoko A. Beran, B.S., M.B.A., CPA qualified, CFO •Ronald Creeley, B.S., Vice President, Marketing & Sales •Michael B. Bolger, Ph.D., Chief Scientist •Jeffrey A. Dahlen, B.E.E., President, Words+, Inc. •Board of directors: -Da
Slide 18: Investment Highlights
Investment Highlights •Emerging, high-growth market•Proprietary multi-platform software•Recurring revenue business model•Fast-growing and profitable•Debt-free•Excellent cash position•World class scientific team•Experienced management team and board
Slide 19: Investment Highlights
Investment Highlights Emerging, high-growth market Proprietary multi-platform software Recurring revenue business model Fast-growing and profitable Debt-free Excellent cash position World class scientific team Experienced management team and board simulationsplus, inc. a